Tarka (AbbVie Inc.)
Welcome to the PulseAid listing for the Tarka drug offered from AbbVie Inc.. This Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | AbbVie Inc. |
NON-PROPRIETARY NAME: | Trandolapril and Verapamil Hydrochloride |
SUBSTANCE NAME: | TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Calcium Channel Antagonists [MoA],Calcium Channel Blocker [EPC],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED, EXTENDED RELEASE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1996-10-22 |
END MARKETING DATE: | 0000-00-00 |
Tarka HUMAN PRESCRIPTION DRUG Details:
Item Description | Tarka from AbbVie Inc. |
LABELER NAME: | AbbVie Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 2; 180(mg/1; mg/1) |
START MARKETING DATE: | 1996-10-22 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0074-3287_95783c64-ca5e-5b93-18c9-e1cae9997778 |
PRODUCT NDC: | 0074-3287 |
APPLICATION NUMBER: | NDA020591 |
Other TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers: